ImmuPharma plc
Total Valuation
GBXAs of December 31, 2025, ImmuPharma plc carries a market capitalization of 3.12B, placing it among publicly traded companies globally. Its enterprise value stands at 2.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.12B |
| Enterprise Value | 2.98B |
Important Dates
ImmuPharma plc's next confirmed earnings release is scheduled for May 25, 2027.
| Earnings Date | 5/25/2027 |
Share Statistics
As of December 31, 2025, ImmuPharma plc has 502.72M shares outstanding.
| Shares Outstanding | 502.72M |
Valuation Ratios
These figures are as of December 31, 2025.
| PB Ratio | 45.38 |
| P/TBV Ratio | 45.38 |
Financial Position
As of December 31, 2025, ImmuPharma plc maintains a current ratio of 1.52, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.52 |
| Quick Ratio | 1.13 |
Stock Price Statistics
GBXAs of the close on October 22, 2026, ImmuPharma plc's stock has declined approximately 66.06% over the past 52 weeks. The 50-day moving average sits at 3.64, while the 200-day moving average is 4.81.
| 52-Week Price Change | -66.06% |
| 50-Day Moving Average | 3.64 |
| 200-Day Moving Average | 4.81 |
Balance Sheet
GBXThese figures are as of December 31, 2025. Total book value stands at 68.69M, with working capital of 62.23M providing operational flexibility.
| Cash & Cash Equivalents | 135.22M |
| Net Debt | -135.22M |
| Equity (Book Value) | 68.69M |
| Book Value Per Share | 0.14 |
| Working Capital | 62.23M |